Skip to main content
Erschienen in: Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 7/2009

01.07.2009 | Leitthema

Individualisierte Prävention des Typ-2-Diabetes

verfasst von: PD Dr. N. Stefan, A. Fritsche, H.-U. Häring

Erschienen in: Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz | Ausgabe 7/2009

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die globale Diabetesprävalenz liegt heute bei 246 Millionen Menschen. Hochrechnungen für das Jahr 2025 sagen 380 Millionen Diabetiker voraus. In Deutschland haben 7 bis 8% der Bevölkerung einen Diabetes. Allerdings geht man von einer hohen Dunkelziffer an unerkanntem Diabetes aus. Die tatsächliche Zahl dürfte in Deutschland bei 7 bis 8 Millionen Diabetikern liegen, was bedeutet, dass etwa jeder 10. Bundesbürger betroffen ist. In den vergangenen Jahren haben mehrere Studien gezeigt, dass eine Prävention des Typ-2-Diabetes möglich ist. Vor allem eine Lebensstilintervention erbrachte diesbezüglich die besten Erfolge. Es gibt sowohl Menschen, die gut auf eine Lebensstilintervention ansprechen, als auch Personen, die hiervon nur wenig profitieren. Die erste Gruppe kann man als „Responder“, letztere als „Non-Responder“ bezeichnen. Mittlerweile gibt es sowohl genetische als auch phänotypische Merkmale, die den Erfolg einer Lebensstilintervention vorhersagen. Somit wird eine individualisierte Prävention des Typ-2-Diabetes möglich.
Literatur
1.
Zurück zum Zitat King H, Aubert RE, Herman WH (1998) Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care Sep 21(9):1414–1431CrossRef King H, Aubert RE, Herman WH (1998) Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care Sep 21(9):1414–1431CrossRef
2.
Zurück zum Zitat Wild S, Roglic G, Green A et al (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27(5):1047–1053PubMedCrossRef Wild S, Roglic G, Green A et al (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27(5):1047–1053PubMedCrossRef
3.
Zurück zum Zitat Rathmann W, Haastert B, Icks A et al (2003) High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA survey 2000. Diabetologia 46(2):182–189PubMed Rathmann W, Haastert B, Icks A et al (2003) High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA survey 2000. Diabetologia 46(2):182–189PubMed
4.
Zurück zum Zitat Cowie CC, Rust KF, Byrd-Holt DD et al (2006) Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health and Nutrition Examination Survey 1999–2002. Diabetes Care 29:1263–1268PubMedCrossRef Cowie CC, Rust KF, Byrd-Holt DD et al (2006) Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health and Nutrition Examination Survey 1999–2002. Diabetes Care 29:1263–1268PubMedCrossRef
5.
Zurück zum Zitat Cowie CC, Rust KF, Ford ES et al (2008) A full accounting of diabetes and prediabetes in the U.S. population, 1988–1994 and 2005–2006. Diabetes Care (Epub ahead of print) Cowie CC, Rust KF, Ford ES et al (2008) A full accounting of diabetes and prediabetes in the U.S. population, 1988–1994 and 2005–2006. Diabetes Care (Epub ahead of print)
6.
Zurück zum Zitat Centers for Disease Control and Prevention (2003) National diabetes fact sheet general information and national estimates on diabetes in the United States, 2003. Centers for Disease Control and Prevention, U.S. Department of Human Services, Atlanta, GA Centers for Disease Control and Prevention (2003) National diabetes fact sheet general information and national estimates on diabetes in the United States, 2003. Centers for Disease Control and Prevention, U.S. Department of Human Services, Atlanta, GA
7.
Zurück zum Zitat Massi-Benedetti M (2002) CODE-2 Advisory Board. The cost of diabetes Type II in Europe: the CODE-2 Study. Diabetologia 45(7):S1–S4PubMedCrossRef Massi-Benedetti M (2002) CODE-2 Advisory Board. The cost of diabetes Type II in Europe: the CODE-2 Study. Diabetologia 45(7):S1–S4PubMedCrossRef
8.
Zurück zum Zitat Narayan KM, Boyle JP, Thompson TJ et al (2003) Lifetime risk for diabetes mellitus in the United States. JAMA 290(14):1884–1890PubMedCrossRef Narayan KM, Boyle JP, Thompson TJ et al (2003) Lifetime risk for diabetes mellitus in the United States. JAMA 290(14):1884–1890PubMedCrossRef
9.
Zurück zum Zitat Yoon KH, Lee JH, Kim JW et al (2006) Epidemic obesity and type 2 diabetes in Asia. Lancet 368(9548):1681–1688PubMedCrossRef Yoon KH, Lee JH, Kim JW et al (2006) Epidemic obesity and type 2 diabetes in Asia. Lancet 368(9548):1681–1688PubMedCrossRef
10.
Zurück zum Zitat Mokdad AH, Bowman BA, Ford ES et al (2001) The continuing epidemics of obesity and diabetes in the United States. JAMA 286(10):1195–1200PubMedCrossRef Mokdad AH, Bowman BA, Ford ES et al (2001) The continuing epidemics of obesity and diabetes in the United States. JAMA 286(10):1195–1200PubMedCrossRef
11.
Zurück zum Zitat Tuomilehto J, Lindstrom J, Eriksson JG et al (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343–1350PubMedCrossRef Tuomilehto J, Lindstrom J, Eriksson JG et al (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343–1350PubMedCrossRef
12.
Zurück zum Zitat Knowler WC, Barrett-Connor E et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403PubMedCrossRef Knowler WC, Barrett-Connor E et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403PubMedCrossRef
13.
Zurück zum Zitat Pan XR, Li GW, Hu YH et al (1997) Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20:537–544PubMedCrossRef Pan XR, Li GW, Hu YH et al (1997) Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20:537–544PubMedCrossRef
14.
Zurück zum Zitat Ramachandran A, Snehalatha C, Mary S et al (2006) The Indian diabetes prevention programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 49(2):289–297PubMedCrossRef Ramachandran A, Snehalatha C, Mary S et al (2006) The Indian diabetes prevention programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 49(2):289–297PubMedCrossRef
15.
Zurück zum Zitat Lindström J, Ilanne-Parikka P, Peltonen M et al (2006) Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 368(9548):1673–1679PubMedCrossRef Lindström J, Ilanne-Parikka P, Peltonen M et al (2006) Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 368(9548):1673–1679PubMedCrossRef
16.
Zurück zum Zitat Uusitupa M, Lindi V, Louheranta A et al (2003) Long-term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance: 4-year results from the Finnish Diabetes Prevention Study. Diabetes 52(10):2528–2532CrossRef Uusitupa M, Lindi V, Louheranta A et al (2003) Long-term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance: 4-year results from the Finnish Diabetes Prevention Study. Diabetes 52(10):2528–2532CrossRef
17.
Zurück zum Zitat Freeman DJ, Norrie J, Sattar N et al (2001) Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103(3):357–362PubMed Freeman DJ, Norrie J, Sattar N et al (2001) Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103(3):357–362PubMed
18.
Zurück zum Zitat Chiasson JL, Brindisi MC, Rabasa-Lhoret R (2005) The prevention of type 2 diabetes: what is the evidence? Minerva Endocrinol 30(3):179–191PubMed Chiasson JL, Brindisi MC, Rabasa-Lhoret R (2005) The prevention of type 2 diabetes: what is the evidence? Minerva Endocrinol 30(3):179–191PubMed
19.
Zurück zum Zitat Buchanan TA, Xiang AH, Peters RK et al (2002) Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 51(9):2796–2803PubMedCrossRef Buchanan TA, Xiang AH, Peters RK et al (2002) Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 51(9):2796–2803PubMedCrossRef
20.
Zurück zum Zitat Gerstein HC, Yusuf S, Bosch J et al (2006) DREAM Diabetes REduction Assessment with ramipril and rosiglitazone Medication Trial Investigators, effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368(9541):1096–1105PubMedCrossRef Gerstein HC, Yusuf S, Bosch J et al (2006) DREAM Diabetes REduction Assessment with ramipril and rosiglitazone Medication Trial Investigators, effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368(9541):1096–1105PubMedCrossRef
21.
Zurück zum Zitat Chiasson JL, Josse RG, Gomis R et al (2002) Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359(9323):2072–2077PubMedCrossRef Chiasson JL, Josse RG, Gomis R et al (2002) Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359(9323):2072–2077PubMedCrossRef
22.
Zurück zum Zitat Torgerson JS, Hauptman J, Boldrin MN, Sjöström L (2004) XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 27(1):155–161PubMedCrossRef Torgerson JS, Hauptman J, Boldrin MN, Sjöström L (2004) XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 27(1):155–161PubMedCrossRef
23.
Zurück zum Zitat Kitabchi AE, Temprosa M, Knowler WC et al (2005) The diabetes prevention program research group. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes 54(8):2404–2414PubMedCrossRef Kitabchi AE, Temprosa M, Knowler WC et al (2005) The diabetes prevention program research group. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes 54(8):2404–2414PubMedCrossRef
24.
Zurück zum Zitat Lindi VI, Uusitupa MI, Lindström J, Finnish Diabetes Prevention Study et al (2002) Association of the Pro12Ala polymorphism in the PPAR-gamma2 gene with 3-year incidence of type 2 diabetes and body weight change in the Finnish Diabetes Prevention Study. Diabetes 51(8):2581–2586PubMedCrossRef Lindi VI, Uusitupa MI, Lindström J, Finnish Diabetes Prevention Study et al (2002) Association of the Pro12Ala polymorphism in the PPAR-gamma2 gene with 3-year incidence of type 2 diabetes and body weight change in the Finnish Diabetes Prevention Study. Diabetes 51(8):2581–2586PubMedCrossRef
25.
Zurück zum Zitat Kubaszek A, Pihlajamäki J, Komarovski V, Finnish Diabetes Prevention Study et al (2003) Promoter polymorphisms of the TNF-alpha (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study. Diabetes 52(7):1872–1876PubMedCrossRef Kubaszek A, Pihlajamäki J, Komarovski V, Finnish Diabetes Prevention Study et al (2003) Promoter polymorphisms of the TNF-alpha (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study. Diabetes 52(7):1872–1876PubMedCrossRef
26.
Zurück zum Zitat Todorova B, Kubaszek A, Pihlajamäki J, Finnish Diabetes Prevention Study et al (2004) The G-250A promoter polymorphism of the hepatic lipase gene predicts the conversion from impaired glucose tolerance to type 2 diabetes mellitus: the Finnish Diabetes Prevention Study. J Clin Endocrinol Metab 89(5):2019–2023PubMedCrossRef Todorova B, Kubaszek A, Pihlajamäki J, Finnish Diabetes Prevention Study et al (2004) The G-250A promoter polymorphism of the hepatic lipase gene predicts the conversion from impaired glucose tolerance to type 2 diabetes mellitus: the Finnish Diabetes Prevention Study. J Clin Endocrinol Metab 89(5):2019–2023PubMedCrossRef
27.
Zurück zum Zitat Mager U, Lindi V, Lindström J, Finnish Diabetes Prevention Study Group et al (2006) Association of the Leu72Met polymorphism of the ghrelin gene with the risk of Type 2 diabetes in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study. Diabet Med 23(6):685–689PubMedCrossRef Mager U, Lindi V, Lindström J, Finnish Diabetes Prevention Study Group et al (2006) Association of the Leu72Met polymorphism of the ghrelin gene with the risk of Type 2 diabetes in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study. Diabet Med 23(6):685–689PubMedCrossRef
28.
Zurück zum Zitat Lindström J, Louheranta A, Mannelin M, Finnish Diabetes Prevention Study Group et al (2003) The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 26(12):3230–3236PubMedCrossRef Lindström J, Louheranta A, Mannelin M, Finnish Diabetes Prevention Study Group et al (2003) The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 26(12):3230–3236PubMedCrossRef
29.
Zurück zum Zitat Herder C, Peltonen M, Koenig W et al (2006) Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes 55(8):2340–2346PubMedCrossRef Herder C, Peltonen M, Koenig W et al (2006) Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes 55(8):2340–2346PubMedCrossRef
30.
Zurück zum Zitat Florez JC, Jablonski KA, McAteer J, Diabetes Prevention Program Research Group et al (2008) Testing of diabetes-associated WFS1 polymorphisms in the Diabetes Prevention Program. Diabetologia 51(3):451–457PubMedCrossRef Florez JC, Jablonski KA, McAteer J, Diabetes Prevention Program Research Group et al (2008) Testing of diabetes-associated WFS1 polymorphisms in the Diabetes Prevention Program. Diabetologia 51(3):451–457PubMedCrossRef
31.
Zurück zum Zitat Stefan N, Kantartzis K, Häring HU (2008) Causes and metabolic consequences of Fatty liver. Endocr Rev 29(7):939–960PubMedCrossRef Stefan N, Kantartzis K, Häring HU (2008) Causes and metabolic consequences of Fatty liver. Endocr Rev 29(7):939–960PubMedCrossRef
32.
Zurück zum Zitat Stefan N, Machicao F, Staiger H et al (2005) Polymorphisms in the adiponectin receptor 1 Gene are associated with insulin resistance and high liver fat. Diabetologia 48(11):2282–2291PubMedCrossRef Stefan N, Machicao F, Staiger H et al (2005) Polymorphisms in the adiponectin receptor 1 Gene are associated with insulin resistance and high liver fat. Diabetologia 48(11):2282–2291PubMedCrossRef
33.
Zurück zum Zitat Stefan N, Kantartzis K, Machann J et al (2008) Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 168(15):1609–1616PubMedCrossRef Stefan N, Kantartzis K, Machann J et al (2008) Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 168(15):1609–1616PubMedCrossRef
34.
Zurück zum Zitat Stefan N, Thamer C, Staiger H et al (2007) Genetic variations in PPARD and PPARGC1A determine mitochondrial function and predict changes in aerobic physical fitness and insulin sensitivity during lifestyle intervention. J Clin Endocrinol Metab 92(5):1827–1833PubMedCrossRef Stefan N, Thamer C, Staiger H et al (2007) Genetic variations in PPARD and PPARGC1A determine mitochondrial function and predict changes in aerobic physical fitness and insulin sensitivity during lifestyle intervention. J Clin Endocrinol Metab 92(5):1827–1833PubMedCrossRef
35.
Zurück zum Zitat Weyrich P, Machicao F, Reinhardt J et al (2008) SIRT1 genetic variants associate with the metabolic response of Caucasians to a controlled lifestyle intervention – the TULIP Study. BMC Med Genet 9:100PubMedCrossRef Weyrich P, Machicao F, Reinhardt J et al (2008) SIRT1 genetic variants associate with the metabolic response of Caucasians to a controlled lifestyle intervention – the TULIP Study. BMC Med Genet 9:100PubMedCrossRef
36.
Zurück zum Zitat Weyrich P, Stefan N, Haring HU et al (2007) Effect of genotype on success of lifestyle intervention in subjects at risk for type 2 diabetes. J Mol Med 85(2):107–117PubMedCrossRef Weyrich P, Stefan N, Haring HU et al (2007) Effect of genotype on success of lifestyle intervention in subjects at risk for type 2 diabetes. J Mol Med 85(2):107–117PubMedCrossRef
37.
Zurück zum Zitat Frayling TM (2007) Genome-wide association studies provide new insights into type 2 diabetes aetiology. Nat Rev Genet 8(9):657–662PubMedCrossRef Frayling TM (2007) Genome-wide association studies provide new insights into type 2 diabetes aetiology. Nat Rev Genet 8(9):657–662PubMedCrossRef
38.
Zurück zum Zitat Florez JC, Jablonski KA, Bayley N, Diabetes Prevention Program Research Group et al (2006) TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med 355(3):241–250PubMedCrossRef Florez JC, Jablonski KA, Bayley N, Diabetes Prevention Program Research Group et al (2006) TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med 355(3):241–250PubMedCrossRef
39.
Zurück zum Zitat Lyssenko V, Jonsson A, Almgren P et al (2008) Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med 359(21):2220–2232PubMedCrossRef Lyssenko V, Jonsson A, Almgren P et al (2008) Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med 359(21):2220–2232PubMedCrossRef
40.
Zurück zum Zitat Kantartzis K, Thamer C, Peter A et al (2008) High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. Gut (Epub ahead of print) Kantartzis K, Thamer C, Peter A et al (2008) High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. Gut (Epub ahead of print)
41.
Zurück zum Zitat Thamer C, Machann J, Stefan N et al (2007) High visceral adipose tissue mass and high liver fat content are associated with resistance to lifestyle intervention. Obesity (Silver Spring) 15(2):531–538 Thamer C, Machann J, Stefan N et al (2007) High visceral adipose tissue mass and high liver fat content are associated with resistance to lifestyle intervention. Obesity (Silver Spring) 15(2):531–538
42.
Zurück zum Zitat Auberger P, Falquerho L, Contreres JO et al (1989) Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity. Cell 58:631–640PubMedCrossRef Auberger P, Falquerho L, Contreres JO et al (1989) Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity. Cell 58:631–640PubMedCrossRef
43.
Zurück zum Zitat Stefan N, Hennige AM, Staiger H et al (2006) Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care 29:853–857PubMedCrossRef Stefan N, Hennige AM, Staiger H et al (2006) Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care 29:853–857PubMedCrossRef
44.
Zurück zum Zitat Hennige AM, Staiger H, Wicke C et al (2008) Fetuin-A induces cytokine expression and suppresses adiponectin production. PLoS ONE 3(3):e1765PubMedCrossRef Hennige AM, Staiger H, Wicke C et al (2008) Fetuin-A induces cytokine expression and suppresses adiponectin production. PLoS ONE 3(3):e1765PubMedCrossRef
45.
Zurück zum Zitat Ix JH, Shlipak MG, Brandenburg VM ET AL (2006) Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. Circulation 113(14):1760–1767PubMedCrossRef Ix JH, Shlipak MG, Brandenburg VM ET AL (2006) Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. Circulation 113(14):1760–1767PubMedCrossRef
46.
Zurück zum Zitat Stefan N, Fritsche A, Weikert C et al (2008) Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes 57(10):2762–2767PubMedCrossRef Stefan N, Fritsche A, Weikert C et al (2008) Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes 57(10):2762–2767PubMedCrossRef
47.
Zurück zum Zitat Stefan N, Häring HU, Schulze MB (2008) Association of fetuin-A level and diabetes risk. JAMA 300(19):2247PubMedCrossRef Stefan N, Häring HU, Schulze MB (2008) Association of fetuin-A level and diabetes risk. JAMA 300(19):2247PubMedCrossRef
48.
Zurück zum Zitat Weikert C, Stefan N, Schulze MB et al (2008) Plasma fetuin-a levels and the risk of myocardial infarction and ischemic stroke. Circulation 118(24):2555–25562PubMedCrossRef Weikert C, Stefan N, Schulze MB et al (2008) Plasma fetuin-a levels and the risk of myocardial infarction and ischemic stroke. Circulation 118(24):2555–25562PubMedCrossRef
49.
Zurück zum Zitat Schulze MB, Hoffmann K, Boeing H et al (2007) An accurate risk score based on anthropometric, dietary, and lifestyle factors to predict the development of type 2 diabetes. Diabetes Care 30(3):510–515PubMedCrossRef Schulze MB, Hoffmann K, Boeing H et al (2007) An accurate risk score based on anthropometric, dietary, and lifestyle factors to predict the development of type 2 diabetes. Diabetes Care 30(3):510–515PubMedCrossRef
50.
Zurück zum Zitat Rathmann W, Martin S, Haastert B et al (2005) Performance of screening questionnaires and risk scores for undiagnosed diabetes: the KORA Survey 2000. Arch Intern Med 165(4):436–4341PubMedCrossRef Rathmann W, Martin S, Haastert B et al (2005) Performance of screening questionnaires and risk scores for undiagnosed diabetes: the KORA Survey 2000. Arch Intern Med 165(4):436–4341PubMedCrossRef
51.
Zurück zum Zitat Rosenzweig JL, Ferrannini E, Grundy SM, Endocrine Society et al (2008) Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 93(10):3671–3689PubMedCrossRef Rosenzweig JL, Ferrannini E, Grundy SM, Endocrine Society et al (2008) Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 93(10):3671–3689PubMedCrossRef
Metadaten
Titel
Individualisierte Prävention des Typ-2-Diabetes
verfasst von
PD Dr. N. Stefan
A. Fritsche
H.-U. Häring
Publikationsdatum
01.07.2009
Verlag
Springer-Verlag
Erschienen in
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz / Ausgabe 7/2009
Print ISSN: 1436-9990
Elektronische ISSN: 1437-1588
DOI
https://doi.org/10.1007/s00103-009-0868-7

Weitere Artikel der Ausgabe 7/2009

Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 7/2009 Zur Ausgabe

Originalien und Übersichten

Die Auswirkungen des Klimawandels

Originalien und Übersichten

Abfallentsorgung in Krankenhäusern

Leitlinien kompakt für die Allgemeinmedizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Facharzt-Training Allgemeinmedizin

Die ideale Vorbereitung zur anstehenden Prüfung mit den ersten 24 von 100 klinischen Fallbeispielen verschiedener Themenfelder

Mehr erfahren

Update Allgemeinmedizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.